NCT06719570View on ClinicalTrials.gov

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions

Healthy

Interventions

DRUG

MK-8591A

Fixed dose combination tablet

DRUG

Islatravir

Oral capsule

DRUG

Doravine

Oral tablet

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06719570 - A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) | Biotech Hunter | Biotech Hunter